Abstract
Mogamulizumab is an anti CCR4 antibody approved for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome (SS) who have tried at least 1 prior systemic therapy. We present 2 cases of vitiligo associated with mogamulizumab. A 76-year-old man with SS previously treated with topical steroids and photopheresis for 2 years was started on mogamulizumab for increased pruritus and a Sézary cell count of 2621. Four months later he developed vitiligo, had an undetectable Sézary cell count, and no pruritus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
